Clin Gastroenterol Hepatol. 2022 Jul;20(7):1606-1608.e2. doi: 10.1016/j.cgh.2021.12.013.Epub 2021 Dec 9.

Trevor L Schell ¹, Luke J Richard ¹, Katharine Tippins ¹, Rachel K Russ ¹, Mary S Hayney ¹, Freddy Caldera ²

Author information

¹Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

²Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: fcaldera@medicine.wisc.edu.

Abstract

Coronavirus disease 2019 (COVID-19) vaccines are recommended for all patients with inflammatory bowel disease (IBD).¹ Patients with IBD historically have had low vaccine uptake relative to the general population.² However, a recent survey suggested a rate higher than that of the general population with regard to COVID-19 vaccine intent among the IBD population. Their study was limited being that 96% of the patients surveyed identified as White, and 88% had attained a bachelor's degree or higher level of education.³ Therefore, these findings may not be representative of the IBD population as a whole. Previous studies have indeed identified disparities in influenza vaccine uptake within the IBD population.^4,5.